Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Cash & Equivalents (2016 - 2017)

Bone Biologics (BBLG) has disclosed Cash & Equivalents for 2 consecutive years, with $1.6 million as the latest value for Q3 2017.

  • On a quarterly basis, Cash & Equivalents rose 135.67% to $1.6 million in Q3 2017 year-over-year; TTM through Sep 2017 was $1.6 million, a 135.67% increase, with the full-year FY2016 number at $620375.0, changed N/A from a year prior.
  • Cash & Equivalents was $1.6 million for Q3 2017 at Bone Biologics, up from $783014.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $4.2 million in Q1 2016 to a low of $620375.0 in Q4 2016.